Phase 3 Data on Bimekizumab for Hidradenitis Suppurativa Show Meaningful Improvements

The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.

Related Keywords

Berlin ,Germany ,United States ,American ,Hidradenitis Suppurativa ,European Hidradenitis Suppurativa Foundation ,Brandenburg Medical School ,American Academy Of Dermatology ,European Academy Of Dermatology ,Analysis Presented ,Bimekizumab Achieved High Thresholds ,Clinical Response ,American Academy ,Dhs ,Bimekizumab ,Phase 3 ,